• Mendus reported a positive readout from the first safety stage of its VITAL-CML trial in chronic-phase CML.
• Results have now been presented via a DSMB review, clearing the combination of vididencel with TKI therapy on safety.
• The outcome supports advancing the pivotal study into an efficacy-focused stage aimed at deepening responses to enable treatment-free remission.
• Additional VITAL-CML readouts are expected in Q4 2026, with initial topline data from all 24 patients expected mid-2027.
• The safety assessment also supports starting the Phase 2a VITAL-TFR2 trial in Q4 2026 for patients with a prior failed remission attempt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mendus AB (publ) published the original content used to generate this news brief on September 11, 2026, and is solely responsible for the information contained therein.